Email

gloria.echeverria@bcm.edu

Positions

Assistant Professor

Baylor College of Medicine
Houston, Texas US

CPRIT Scholar in Cancer Research

Cancer Prevention and Research Institute of Texas (CPRIT)

Member

Lester and Sue Smith Breast Center

Member

Dan L. Duncan Cancer Center

Member

Department of Medicine

Member

Department of Molecular and Cellular Biology

Member

Department of Radiation Oncology

Addresses

Office: R516 (Lab)

One Baylor Plaza
Houston, TX 77030
United States
gloria.echeverria@bcm.edu
Echeverria Lab website

Office: R516 (Office)

One Baylor Plaza
Houston, TX 77030
United States
gloria.echeverria@bcm.edu
Echeverria Lab website

Education

BS from Texas A&M University

05/2008 - College Station, Texas United States

PhD from Baylor College of Medicine

10/2013 - Houston, Texas United States

Postdoctoral Fellowship at The University of Texas MD Anderson Cancer Center

12/2019 - Houston, Texas United States

Professional Statement

The Echeverria laboratory investigates the metabolic and phenotypic plasticity of triple negative breast cancer (TNBC) that is refractory to conventional therapeutic treatments. The focus of the lab is to delineate the molecular and cell biological mechanisms underpinning mitochondrial and metabolic adaptations of TNBC using state-of-the art patient-derived xenograft mouse models and in vitro cultured human TNBC cells. The lab utilizes high-resolution microscopy, genome engineering, single-cell technologies, multiplexed tissue imaging, and metabolomics with the ultimate goal of combating tumor evolution to improve the lives of women living with TNBC.

Websites

Selected Publications

• Baek M, Lee JG, Pendleton KE, Berner MJ, Goff EB, Tan L, Martinez SA, Wang T, Meyer M, Lim B, Barrish JP, Lorenzi P, Porter W, Echeverria GV "Mitochondrial structure and function adaptation in residual triple negative breast cancer cells surviving chemotherapy treatment." 2023 Feb; Pubmed PMID: 36813854
• Echeverria GV, Ge Z, Seth S, Zhang X, Jeter-Jones S, Zhou X, Cai S, Tu Y, McCoy A, et al. "Resistance to neoadjuvant chemotherapy in triple-negative breast cancer mediated by a reversible drug-tolerant state." Sci Transl Med. 2019; Pubmed PMID: 30996079
• Echeverria GV*, Cai S, Tu Y, Shao J, Powell E, Redwood A, Jiang Y, McCoy A, Rinkenbaugh A, Lau R, Trevarton A, Fu X, Gould R, Adrada B, Lane D, auch G, ang Q, Whie J, Chang JT, Moulder S, Symmans WF, Hilsenbeck SG, Piwnica-Worms H* "Predictors of success in establishing orthotopic patient-derived xenograft models of triple negative breast cancer from fine needle tumor aspirates." 2023; Pubmed PMID: 36627285
• Anurag M, Jaehnig E, Krug K, Lei JT, Bergstrom E, Kim BJ, Vashist T, Huynh A, Dou YU, Gou X, Huang C, Shi Z, Wen B, Korchina V, Gibbs R, Mani DR, Gilette MA, Zhang B, Echeverria GV, Miles G, Rimawi MF, Carr SA, Ademuyiwa FO, Satpathy S, and Ellis MJ "Proteogenomic markers of chemotherapy resistance and response in triple negative breast cancer." 2022; Pubmed PMID: 36001024

Funding

R37 MERIT Award

(12/22/2022 - 12/21/2025) Grant funding from NCI

Research Scholar Grant

(02/01/2023 - 01/31/2027) Grant funding from American Cancer Society

First-Time Faculty Recruitment Award

Grant funding from CPRIT

SPORE Career Enhancement Program Award

(08/01/2022 - 05/31/2023) Grant funding from NCI